Delivery Order SPE2DB22D3501-SPE2DB25FXN02
- Not listed
- The Defense Logistics Agency awarded a $35,153.85 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. The contract, which is non-set-aside and competitively awarded, carries an ultimate completion date of September 3, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $4.7K delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injections. This competitively awarded, firm fixed-price contract carries an ultimate completion date of September 29, 2025, and will be fulfilled at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $4,687.18 delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors with an ultimate completion date of September 11, 2025. This competitive award was issued under a firm fixed-price contract structure with no set-aside designation. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen injectors, with an ultimate completion date of September 12, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's larger prime contract vehicle with DLA. The pharmaceutical products will be delivered to AmerisourceBergen's corporate headquarters location in...
- The Defense Logistics Agency awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pen injectors, with an ultimate completion date of September 16, 2025. The contract was competitively awarded without set-aside designation and operates under a firm fixed price structure. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order at its corporate office location....
- The Defense Logistics Agency awarded a delivery order valued at $14,061.54 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pen injectors on September 2, 2025, with completion expected by September 23, 2025. This competitive delivery order represents a firm fixed-price transaction issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999,999,999 global pharmaceutical support vehicle running through December 2026. The SPE2DX...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Tezspire 210 mg/1.91 ml pen injectors, valued at $2,343.59, with an ultimate completion date of September 16, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to federal medical procurement needs. The contract is performed from the company's corporate...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $4,687.18 for Tezspire 210 mg/1.91 mL pen injectors, with a completion date of August 19, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Tezspire is a specialty biologic medication used in the treatment of severe asthma, representing the type of high-value...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,030.77 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pen injectors, with an ultimate completion date of May 14, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is being fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $2,343.59 on August 18, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. This is a firm fixed price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of September 9, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FXN02Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,687.18 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen injectors, with an ultimate completion date of October 17, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a single delivery order under a larger indefinite delivery vehicle. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement needs across the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. This delivery order is issued under AmerisourceBergen's prime indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The broader contract vehicle provides comprehensive global pharmaceutical support to military healthcare programs, encompassing specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains. Tezspire is a biologic asthma treatment, reflecting the company's portfolio of specialized pharmaceutical products supporting military and veteran healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.7k | 9/25/25 |